Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent Influenza Split Virion Vaccine Phase III Trial in ≥3-year-old Healthy Population
CTR20230911Phase 3Completed
- Sponsor
- Shenzhen Kangtai Biological Products
- Start
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of influenza vaccine (split virion, inactivated, quadrivalent) in influenza, sponsored by Shenzhen Kangtai Biological Products. Started Apr 2023; status: completed.
02
Drugs
influenza vaccine (split virion, inactivated, quadrivalent)
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20230911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230911.